We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Biogen Resurrects Alzheimer’s Drug for FDA Approval
Biogen Resurrects Alzheimer’s Drug for FDA Approval
Biogen has decided to renew its bid for FDA approval in early 2020 of its investigational anti-amyloid Alzheimer’s drug aducanumab after halting clinical trials earlier this year.